The Myocardial Ischemia drugs in development market research report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Myocardial Ischemia. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Myocardial Ischemia by 11 companies/universities/institutes. The top development phase for Myocardial Ischemia is preclinical with seven drugs in that stage. The Myocardial Ischemia pipeline has ten drugs in development by companies and one by universities/ institutes. Some of the companies in the Myocardial Ischemia pipeline products market are: Chrysalis BioTherapeutics, BioCardia and University Hospital Geneva.
The key targets in the Myocardial Ischemia pipeline products market include Receptor Type Tyrosine Protein Phosphatase S, Nitric Oxide Synthase Inducible, and Gap Junction Alpha 1 Protein.
The key mechanisms of action in the Myocardial Ischemia pipeline product include Nitric Oxide Synthase Inducible Inhibitor with one drug in Preclinical. The Myocardial Ischemia pipeline products include six routes of administration with the top ROA being Oral and six key molecule types in the Myocardial Ischemia pipeline products market including Gene Therapy, and Small Molecule.
Myocardial Ischemia overview
Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris); neck or jaw pain; shoulder or arm pain; clammy skin; shortness of breath; and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clots, coronary spasms, and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include smoking, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity, and family history.
For a complete picture of Myocardial Ischemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
